Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa,...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

lydia1972 Aug. 5 at 2:41 PM

$IFRX und jeden Tag wieder das selbe. Das ist nicht normal

0 · Reply

levystrauss Aug. 5 at 2:26 PM

$IFRX

0 · Reply

dogDazeSummer Aug. 5 at 2:12 PM

$IFRX seems as if Stadison would be an ideal buyer for entire company. Who else knows better how the mechanism works? Plus with stock run up valued over $3B USD- they could take advantage and do a secondary offering— pay all cash for Inflarx. Then have rights to whole world and pay themselves royalties. Their buy price would theoretically be reduced by any cash payments due to Inflarx.

2 · Reply

Barkingdogs Aug. 5 at 12:55 PM

$IFRX MC Hammer "Can't Touch This!"

0 · Reply

TimmyT412 Aug. 4 at 7:46 PM

$IFRX do not invest or trade this company if you like to make money. Lol

1 · Reply

cielo1 Aug. 4 at 5:32 PM

$IFRX low volume suggests wait and see in the meantime lets get above $1...

1 · Reply

Bigdawg_16 Aug. 4 at 5:10 PM

@Santa_Claus_Trades $IFRX what you think about this stock?

1 · Reply

Barkingdogs Aug. 4 at 4:40 PM

$IFRX if u r not in U R OUT

0 · Reply

levystrauss Aug. 4 at 4:39 PM

$IFRX 👇🏻🤡🤦‍♂️🤷‍♀️🤞

0 · Reply

levystrauss Aug. 4 at 4:38 PM

$IFRX That said, I'd be the first to be happy if there's good news. But to celebrate, we need to recover all the money we're losing. Compassion bought at $30, others have been here for five years at $15, others like the RJ fund at $4.25, all at huge losses. Only at $5-6 can we start to be positive. But with this CEO, so far, it's only losses for everyone.

2 · Reply

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jul 11, 2025, 4:15 PM EDT - 24 days ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

May 28, 2025, 11:00 AM EDT - 2 months ago

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

May 28, 2025, 1:30 AM EDT - 2 months ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 2 months ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 7:30 AM EDT - 3 months ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 3 months ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 7:30 AM EDT - 4 months ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 5 months ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 5 months ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 5 months ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 5 months ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 6 months ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 6 months ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 6 months ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 7 months ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 8 months ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Nov 15, 2024, 7:51 AM EST - 9 months ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 8, 2024, 7:30 AM EST - 9 months ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 11 months ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 1 year ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 1 year ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 1 year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Mar 21, 2024, 7:00 AM EDT - 1 year ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

Mar 19, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Feb 22, 2024, 7:30 AM EST - 1 year ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Jan 25, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Jan 4, 2024, 7:00 AM EST - 1 year ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Nov 6, 2023, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 1, 2023, 7:30 AM EDT - 1 year ago

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 11, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Sep 6, 2023, 5:31 PM EDT - 2 years ago

InflaRx: Small German Company Targeting A Rare Indication

Aug 30, 2023, 7:30 AM EDT - 2 years ago

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Aug 10, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

Jun 28, 2023, 7:30 AM EDT - 2 years ago

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Jun 21, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

May 16, 2023, 4:00 AM EDT - 2 years ago

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

May 11, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Apr 18, 2023, 4:01 PM EDT - 2 years ago

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

Apr 14, 2023, 4:01 PM EDT - 2 years ago

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023, 9:08 PM EDT - 2 years ago

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023, 4:00 PM EDT - 2 years ago

InflaRx Announces Public Offering of Ordinary Shares

Apr 4, 2023, 2:55 PM EDT - 2 years ago

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Mar 22, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Full Year 2022 Financial and Operating Results

lydia1972 Aug. 5 at 2:41 PM

$IFRX und jeden Tag wieder das selbe. Das ist nicht normal

0 · Reply

levystrauss Aug. 5 at 2:26 PM

$IFRX

0 · Reply

dogDazeSummer Aug. 5 at 2:12 PM

2 · Reply

Barkingdogs Aug. 5 at 12:55 PM

$IFRX MC Hammer "Can't Touch This!"

0 · Reply

TimmyT412 Aug. 4 at 7:46 PM

$IFRX do not invest or trade this company if you like to make money. Lol

1 · Reply

cielo1 Aug. 4 at 5:32 PM

$IFRX low volume suggests wait and see in the meantime lets get above $1...

1 · Reply

Bigdawg_16 Aug. 4 at 5:10 PM

@Santa_Claus_Trades $IFRX what you think about this stock?

1 · Reply

Barkingdogs Aug. 4 at 4:40 PM

$IFRX if u r not in U R OUT

0 · Reply

levystrauss Aug. 4 at 4:39 PM

$IFRX 👇🏻🤡🤦‍♂️🤷‍♀️🤞

0 · Reply

levystrauss Aug. 4 at 4:38 PM

2 · Reply

levystrauss Aug. 4 at 4:36 PM

$IFRX We were at 6 dollars 2 years ago and the CEO made the stock collapse to 0.91, there is little to celebrate

0 · Reply

Barkingdogs Aug. 4 at 4:34 PM

$IFRX 85% REDucTION in HIGH RISK GROUP!!!

0 · Reply

Barkingdogs Aug. 4 at 4:24 PM

$IFRX earnings this week mean nothing it's all about ARDs

0 · Reply

Barkingdogs Aug. 4 at 4:21 PM

$IFRX once this goes you will be chasing it because there is very little stock for sale and when the institutions move in it jumps by dollars not cents

0 · Reply

Barkingdogs Aug. 4 at 3:59 PM

$IFRX Staidson (Beijing) BioPharmaceuticals (SHE:300204) released the preliminary results for clinical trials for a drug that will treat patients with acute respiratory distress syndrome or ARDS, according to a Shenzhen bourse filing on Wednesday. The Phase Ib/II clinical trials, which evaluates the safety and efficiency of the STSA-1002 injection, found that the drug showed mortality reductions of 33% and 85% for the low-dose and high-dose groups, respectively. The drug also showed clinical improvement rates of more than 70% for both groups. The clinical trials received approval from the Chinese drug administration in March, the biopharmaceutical company said. Staidson Bio's shares surged 20% in recent trade.

2 · Reply

morgueana Aug. 4 at 3:51 PM

$IFRX Staidson now 26B market cap--

1 · Reply

MrCompassion Aug. 4 at 2:16 PM

$IFRX Never been much of anything from InflaRx in August except for Q2 financials. The one exception was Aug 10, 2021, when they released some PG p2 data. Let’s see a repeat in 2025. My hope is to see PG p3 topline results before release of the INF904 p2a data. We need to see resolution on this whole complete ulcer closure mess that led to a futility stop that in turn suggests to the general market that Vilo fails at the very thing it’s designed to do: significantly reduce neutrophil hyperactivity that otherwise causes neutrophilic dermatoses such as PG and HS. Here’s the presentation material given back in Oct 2021: https://web.archive.org/web/20220513150241/https://www.inflarx.de/dam/jcr:a8b23b92-6dc6-470b-acef-accd741753da/20211027_InflaRx_conferencecall.pdf Low dose saw 2 of 6 hit PGA=0, completely clear, but one of them started out at PGA=3. Without more details – like ulcer size to start with, etc. – what’s to be concluded? Medium dose: 1 of 4 but only after being up-titrated to high dose. High dose: 0 of 7 hit sustained PGA=0 (ironically) but the

2 · Reply

cielo1 Aug. 4 at 1:30 PM

$IFRX "Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned." No confernce call makes it seems as though no substantial news...?? Let's see some stellar news in the days ahead! 38 days left of summer! Partnership or buyout seems crazy Roche or Staidson has not taken them for a few billion already...! In the words of Staindson these mabs e.g. Gohibic INF904 are revolutionary! As we know Staidson stock price has skyrocketed on their prelim mab news. We need stellar managment/resources to accelerate commercialization of the pipeline -stat! Mega

1 · Reply

IgnantCrewTycoon Aug. 4 at 11:23 AM

$IFRX

0 · Reply

levystrauss Aug. 4 at 10:01 AM

$IFRX This

0 · Reply

levystrauss Aug. 4 at 10:00 AM

$IFRX

0 · Reply

Barkingdogs Aug. 4 at 2:50 AM

$IFRX you realize bashers are shills trying to buy your stock when you read there BS and just about sht yourself, so you freak out and sell to them. Why else hang out and bash??? They want your stock very close....🤑🤑🤑🤑

0 · Reply

Market Cap	57.73M
Revenue (ttm)	180,000.00
Net Income (ttm)	-49.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27,694.44%
Debt to Equity Ratio	0.00

Volume	96,100
Avg Vol	538,366
Day's Range	N/A - N/A
Shares Out	67.13M
Stochastic %K	51%
Beta	1.29
Analysts	Strong Sell
Price Target	$3.80